Paclitaxel CAS#33069-62-4
1. Targeted Action: Specifically binds to polymerized microtubules, promoting their stabilization and disrupting cell division.
2. Cancer Treatment Efficacy: Proven effectiveness against ovarian, breast, non-small cell lung, colorectal, and other cancers.
3. Cell Cycle Arrest: Induces cell cycle arrest at the mitotic phase, preventing cancer cell division and growth.
4. Clinical Success: Widely used in advanced cancer therapies, with established efficacy in Phase II-III clinical trials.
Paclitaxel is a diterpenoid monomer isolated from the bark of Taxus species. As a structurally complex secondary metabolite, it represents the only known therapeutic agent capable of both promoting microtubule polymerization and stabilizing the resultant microtubule structures. Isotopic labeling studies demonstrate that paclitaxel specifically binds to polymerized microtubules without interacting with free tubulin dimers.
Cellular exposure to paclitaxel induces massive intracellular microtubule accumulation, which disrupts multiple cellular processes - most notably arresting cell cycle progression at the mitotic phase, thereby inhibiting normal cell division. Clinical trials (Phase II-III) have established its primary efficacy against ovarian and breast carcinomas, with demonstrated activity against various malignancies including non-small cell lung cancer, colorectal carcinoma, melanoma, head and neck cancers, lymphomas, and gliomas.
Parameters
Melting point | 213 °C (dec.)(lit.) |
alpha | D20 -49° (methanol) |
Boiling point | 774.66°C (rough estimate) |
density | 0.2 |
refractive index | -49 ° (C=1, MeOH) |
Fp | 9℃ |
storage temp. | 2-8°C |
solubility | methanol: 50 mg/mL, clear, colorless |
form | |
pka | 11.90±0.20(Predicted) |
color | white |
Water Solubility | 0.3mg/L(37 ºC) |
λmax | 227nm(MeOH)(lit.) |
Merck | 146982 |
BRN | 1420457 |
Stability: | Stable. Incompatible with strong oxidizing agents. Combustible. |
InChIKey | RCINICONZNJXQF-MZXODVADSA-N |
LogP | 3.950 (est) |
CAS DataBase Reference | 33069-62-4(CAS DataBase Reference) |
EPA Substance Registry System | Paclitaxel (33069-62-4) |
Safety Information | |
Hazard Codes | Xn |
Risk Statements | 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22 |
Safety Statements | 22-26-36/37/39-45 |
RIDADR | 1544 |
WGK Germany | 3 |
RTECS | DA8340700 |
F | 45951 |
HazardClass | 6.1(b) |
PackingGroup | III |
HS Code | 29329990 |
Hazardous Substances Data | 33069-62-4(Hazardous Substances Data) |
Toxicity | LD50 intraperitoneal in mouse: 128mg/kg |
